Asparkam - instructions for use, dose, side effects, contraindications

Pharmacodynamics:Asparta is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is presumably associated with the role of aspartate as a carrier of magnesium and potassium ions in the intracellular space and with the participation of aspartate in metabolic processes. Thus, Asparkam eliminates the imbalance of electrolytes, reduces the excitability and conductivity of the myocardium (moderate antiarrhythmic effect).

Pharmacokinetics:

Easily absorbed when ingested and relatively quickly excreted by the kidneys.

Indications:

Asparkam is used in complex therapy for heart failure, coronary heart disease, to eliminate the deficiency of potassium and magnesium, heart rhythm disorders (including myocardial infarction, cardiac glycoside overdose).

Contraindications:

Hypersensitivity to the components of the drug, impaired metabolism of amino acids, acute and chronic renal failure, hyperkalemia, hypermagnesia, insufficiency of the adrenal cortex, violation of atrioventricular conduction (AV blockade I-III ), severe myasthenia gravis, hemolysis, severe arterial hypotension (systolic blood pressure less than 90 mm Hg), age to 18 years.

Carefully:

Pregnancy, lactation.

Dosing and Administration:

Aspartame is prescribed inside, after eating. Adults take 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks. If necessary, repeat the course.

Side effects:

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the pancreas (in patients with an anatomic gastritis or cholecystitis), atrioventricular blockade, paradoxical reaction (increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea,parasthesia), hypermagnesia (redness of the face, thirst, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions).

Overdose:

Symptoms: hyperkalemia (nausea, vomiting, diarrhea, abdominal pain, metallic taste in the mouth, bradycardia, weakness, disorientation, muscle paralysis, paresthesia of the limbs, slowing of atrioventricular conduction, cardiac arrest)) and hypermagneemia (redness of the face, thirst, arterial hypotension, hyporeflexia, impaired neuromuscular transmission, respiratory depression, arrhythmia, convulsions).

Early clinical signs of hyperkalemia usually appear at a K + concentration in the serum of more than 6 meq / l: tapering of the T wave, disappearance of the prong U, segment decline S-T, interval elongation Q-T, expansion of the complex QRS. More severe symptoms of hyperkalemia - muscle paralysis and cardiac arrest - develop at a concentration of K + 9-10 meq / L.

Treatment: withdrawal of the drug, symptomatic therapy (iv administration of calcium chloride solution at a dose of 100 mg / min), if necessary - hemodialysis, peritoneal dialysis.

Interaction:

Pharmacodynamic: joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin converting enzyme inhibitors, non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole.

The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Due to the content of potassium ions, the undesirable effects of cardiac glycosides decrease. Due to the content of magnesium ions reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracurium bezylate, decamethonium bromide, suxamethonium (chloride, bromide, iodide). Calcitriol increases the concentration of magnesium ions in the blood plasma, calcium preparations reduce the effect of magnesium.

Pharmacokinetic: astringent and enveloping agents reduce the absorption of the drug in the gastrointestinal tract (a 3-hour interval between their intake must be observed).

Special instructions:

It is necessary to control the content of potassium and magnesium ions in the blood plasma.

Effect on the ability to drive transp. cf. and fur:

Clinical studies to assess the effect of the drug on the ability to manage vehicles and mechanisms have not been conducted.

Form release / dosage:Pills.

Packaging:

For 10 tablets in a contour non-jammed package of paper with a polymer coating. For 10 tablets in a contoured cell pack of a polyvinylchloride film and aluminum foil or paper with a polymer coating.

For 50 tablets in a polymer-type polymer jar or in a dark-colored glass bottle of BTS type, sealed with a plastic pull-on lid.

Each jar or 1, 2, 3 or 5 contour packs, together with the instruction for use, is placed in a pack of cardboard.

Storage conditions:

In a dry place, at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:P N000383 / 01

Date of registration:21.05.2012

Expiration Date:Unlimited

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Information update date: & nbsp17.10.2017

Illustrated instructions

Instructions

Aspark (Asparcam)